Hairy cell leukemia is an uncommon malignancy of hematopoietic stem cells, named for the fine, hair-like projections that cover the surface of the malignant cells. It predominantly affects men and is driven in nearly all cases by a single acquired mutation, BRAF V600E, which was identified more than a decade ago and has since become both a diagnostic marker and a therapeutic target. The disease has a remarkable treatment history: described first in 1923, it was initially managed with splenectomy, then advanced through interferon and the purine analog pentostatin before cladribine, a nucleoside analog that is toxic to lymphocytes, became the backbone of therapy. More recently, combinations of cladribine with the monoclonal antibody rituximab have pushed remission rates even higher, and BRAF inhibitors such as vemurafenib have shown excellent results in refractory cases. Yet for all these advances, the standard cladribine schedule, a continuous infusion given on five to seven consecutive days, has remained essentially unchanged for two decades.

That constancy has persisted despite a persistent problem: toxicity. Cladribine profoundly depletes normal white blood cells, particularly neutrophils, leaving patients vulnerable to serious bacterial infections. Many require hospitalization, intravenous antibiotics, growth factor support, and blood product transfusions during the weeks following treatment. The concern became acute roughly fifteen years ago when deaths occurred among patients receiving continuous cladribine infusions. This prompted a handful of investigators to ask whether the same drug, delivered as one weekly outpatient infusion instead of daily doses, might achieve comparable disease control with far less collateral damage. The idea has biological logic: cladribine is a long-acting drug that accumulates in lymphocytes, and stretching its delivery across weeks may moderate the depth and duration of immunosuppression without compromising the lethal effect on malignant cells. Prior studies comparing the two schedules, including two prospective randomized trials from European groups, produced mixed results, with some finding no significant difference in efficacy and others reporting fewer neutropenic and infectious complications with weekly dosing.

The new study, led by Jacqueline A. Turner and colleagues including William A. Robinson, adds substantially to this literature by combining treatment response data with long-term survival analysis and modern molecular monitoring. The researchers identified 36 treatment-naïve patients with hairy cell leukemia treated at their institution since 2002. Eighteen received intermittent cladribine, meaning one infusion per week for 5 to 7 weeks, while 18 received the standard continuous schedule of daily outpatient infusions over 5 to 7 days. The groups were broadly similar at baseline: 83.3 percent of patients in each group were male, and initial white blood cell counts, hemoglobin concentrations, and platelet counts were statistically indistinguishable. The median age at diagnosis differed notably, at 58 years in the weekly-dosing group versus 45 years in the continuous group, a disparity the authors acknowledge may reflect shifting referral patterns over the two-decade study window.

The efficacy results favored weekly dosing on every clinically meaningful measure tested. Beyond the difference in complete remission rates, 94.4 percent versus 61.1 percent, no patient in the weekly group experienced progressive disease, while 38.9 percent of the continuous-infusion group did. Kaplan-Meier analysis showed no difference in overall survival between the groups, a finding the authors attribute to the effectiveness of salvage therapies at relapse, but progression-free survival differed profoundly, with a p-value below 0.0001 by log-rank testing. Hospitalizations during treatment induction were less frequent with weekly dosing, affecting 4 of 18 patients compared with 6 of 18, and among three patients in the study who had relapsed after continuous cladribine and were later re-challenged with the weekly schedule, all achieved complete responses, with two remaining in remission for years and none requiring hospitalization during the weekly regimen, in contrast to hospitalizations and neutropenic fevers that had complicated their original continuous-infusion treatment.

Toxicity data painted a more nuanced picture. Neutropenia was nearly universal in both groups, affecting 88.9 percent of weekly-dosing patients and 92.9 percent of continuous-infusion patients with recorded data, and neutropenic fever occurred in roughly 43 to 44 percent of both groups. Antibiotic use was identical at 50 percent, and the proportion of patients requiring growth factor support or blood product transfusions was also comparable. This raises an important interpretive question, because the weekly group was far more likely to have received rituximab after cladribine, 72.2 percent versus 27.2 percent, a chemoimmunotherapy addition that has itself been shown to deepen remissions and extend survival. The authors are candid about this limitation, noting that the non-randomized design and the imbalance in rituximab exposure may have contributed to the observed differences and preclude definitive conclusions about which element of the regimen drives the benefit.

The study also offers a window into the future of disease monitoring in hairy cell leukemia. In a subset of more recently treated patients, the team used quantitative polymerase chain reaction on peripheral blood samples to track the frequency of the mutant BRAF V600E allele, essentially using the driver mutation itself as a measurable residual disease marker. At five years after treatment, all tested patients in both groups had undetectably low levels of the mutant allele, and the decline in mutant allele burden correlated closely with clinical remission. Because the assay requires only a blood draw, the authors argue it could serve as a less invasive alternative to the repeated bone marrow biopsies traditionally used to assess remission depth, and they recommend that serial BRAF mutant allele frequency testing be incorporated into routine care. The feasibility of monitoring relapse through a simple blood test is particularly attractive in a disease whose treatment is most effective when started early.

The rarity of hairy cell leukemia complicates the path forward. With only a few thousand new cases diagnosed annually in the United States, prospective randomized trials comparing the two schedules are difficult to mount and slow to accrue, which helps explain why the question has lingered for decades with only mixed and limited answers. The two previously conducted randomized trials, from the Polish Adult Leukemia Group and the Swiss Group for Clinical Cancer Research, found no significant efficacy differences, while earlier Italian work by Lauria and colleagues and by Zinzani and colleagues reported that weekly administration reduced infectious complications. The Colorado experience, with its extended follow-up and favorable progression-free survival signal, tilts the accumulated evidence somewhat further toward the weekly schedule, though the authors concede that confirmation in larger, prospective, ideally multi-institutional cohorts would be valuable and have committed to continuing to expand and update their own series.

For patients, the practical implications are appealing regardless of which component of the regimen proves decisive. A once-weekly outpatient infusion eliminates the logistical burden of consecutive daily hospital visits, and the reduced hospitalization rate translates into fewer exposures to drug-resistant hospital pathogens for an already immunocompromised population. Because most hairy cell leukemia patients are older and carry comorbidities, the authors emphasize that an ideal regimen must be both effective and low-risk across short- and long-term horizons, criteria they argue weekly cladribine followed by rituximab appears to meet. Their conclusion is measured but hopeful: the weekly schedule represents a feasible strategy supported by institutional experience, and while randomized validation would be ideal, the totality of the data, higher complete remission rates, superior progression-free survival, comparable overall survival and toxicity, and fewer hospitalizations, suggests a genuine clinical benefit that the field should not ignore.

The study arrives at a moment when the treatment of hairy cell leukemia is already undergoing a molecular renaissance, driven by the discovery that a single point mutation powers the disease and by the growing clinical repertoire of BRAF inhibitors and antibody combinations. Against that backdrop, the Colorado findings are a reminder that sometimes meaningful progress in oncology comes not from new molecules but from new ways of using old ones. Cladribine has been a mainstay of hairy cell leukemia therapy since the early 1990s, and if simply rearranging its administration calendar can keep more patients in durable remission with fewer trips to the hospital, the change would cost essentially nothing to implement. Whether weekly cladribine followed by rituximab formally becomes the new standard will depend on the larger studies the authors call for, but for a disease that has long been a treatment success story, this work proposes a way to make the story even better.

Diffuse large B-cell lymphoma, classified as a type of non-Hodgkin lymphoma, has long posed challenges for oncologists due to its heterogeneous nature and varying responses to standard therapies. Traditional treatment methods generally include R-CHOP, a regimen that combines rituximab with chemotherapy. However, despite initial success, many patients ultimately relapse or experience insufficient responses, necessitating exploration of innovative combinations to enhance treatment outcomes.

The study in focus looked at the efficacy of this three-drug combination as a first-line treatment for newly diagnosed DLBCL patients, especially in the context of molecular advancements and better understanding of tumor biology. The retrospective nature of the analysis provided a real-world perspective by examining outcomes from patients treated over a defined period in a single-center institution, ensuring consistency and thorough data collection.

One of the remarkable aspects of including a BTK inhibitor in the regimen is its mechanism of action. BTK plays a pivotal role in B-cell receptor signaling, which is fundamental to the survival and proliferation of malignant B-cells. By inhibiting this pathway, researchers aimed to disrupt the survival signals that permit DLBCL cells to thrive and evade destruction. This approach, combined with the longstanding efficacy of rituximab—as an anti-CD20 monoclonal antibody—and lenalidomide, known for its immunomodulatory properties, presents a multifaceted attack on the cancer.

The findings reflect an encouraging response rate among the subjects, providing a solid foundation for future prospective trials. Not only did merging these agents result in a significant reduction in tumor burden, but the study also highlighted a favorable safety profile, which is a crucial consideration when evaluating new therapeutic strategies. Adverse events, expected in such treatments, were documented but appeared manageable, indicating that this combination could potentially redefine front-line therapies.

Through rigorous statistical analyses, the research team was able to demonstrate improved progression-free survival rates when compared to historical controls treated with standard regimens. Such results might guide oncologists in considering BTK inhibitors as integral components of treatment plans tailored for DLBCL patients. This is particularly relevant in cases where genetic mutations or pathways show potential resistance to conventional therapies.

Moreover, the study prompts a reevaluation of existing treatment protocols and opens pathways for personalized medicine. Investigators are keen to explore biomarkers that could predict which patients might respond best to this combination therapy, ultimately enhancing individual patient outcomes. The incorporation of precision medicine aligns with ongoing efforts to shift away from one-size-fits-all approaches and move towards strategies tailored based on the specific genetic and molecular profiling of tumors.

Despite the optimism surrounding the study’s findings, the researchers underscore the necessity for larger, multicentric trials to further corroborate these results. Such studies can facilitate the validation of these combinations across diverse populations and help ascertain any long-term benefits or latent risks associated with prolonged treatment regimens. Peer-reviewed publications and conferences may soon become platforms for sharing the expanded data, potentially influencing clinical practice guidelines.

The study also raises intriguing questions about potential mechanisms of resistance to this therapy. Understanding how and why certain patients experience recurrences is crucial to developing next-generation treatment paradigms. Continuous monitoring of long-term outcomes will be imperative, as insights gleaned from patient experiences can inform future research directions.

In summary, the incorporation of BTK inhibitors into combination therapy for newly diagnosed DLBCL represents an exciting frontier in oncological research. The positive findings of this retrospective study provide a compelling argument for rethinking traditional paradigms and exploring more integrative approaches. It heralds a new era of possibility for patients afflicted by this challenging and often deadly disease, illuminating a path toward enhanced survival and quality of life.

Researchers remain optimistic as they embark on further investigations to pinpoint the ideal patient profiles for this treatment and refine therapeutic combinations. The quest for improved outcomes in diffuse large B-cell lymphoma continues, driven by both innovation and the unwavering commitment of the scientific community to turn the tide against this formidable adversary.

In light of the evolving therapeutic landscape, physicians and patients alike anticipate further advancements that could emerge from this promising research, waiting for the next wave of breakthroughs that will pave smoother paths to remission and recovery for those battling DLBCL.

As follow-up studies unfold, the urgency to standardize new treatment protocols will grow, reinforcing the importance of collaboration among researchers, clinicians, and patients. The aspiration to revolutionize DLBCL treatment is no longer a distant dream but a tangible reality, fueled by the dedicated work of researchers like Lv, Zhu, and Yang, along with their teams.

Ultimately, the future of DLBCL treatment is intertwined with continued innovation and the relentless pursuit of knowledge. These exciting developments stand as a testament to the power of scientific inquiry and the endless potential for improvement in patient care. As more data accumulate, the hope is not merely to extend lives but to enhance the quality of life for all those affected by this formidable disease.

Subject of Research: Efficacy of BTK inhibitor combined with rituximab and lenalidomide in newly diagnosed diffuse large B-cell lymphoma.

Article Title: Efficacy of BTK inhibitor combined with rituximab and lenalidomide in newly diagnosed diffuse large B-cell lymphoma: a single-center, retrospective study.

Article References:

Lv, Y., Zhu, Y., Yang, C. et al. Efficacy of BTK inhibitor combined with rituximab and lenalidomide in newly diagnosed diffuse large B-cell lymphoma: a single-center, retrospective study.
Ann Hematol 105, 33 (2026). https://doi.org/10.1007/s00277-026-06826-3

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s00277-026-06826-3

Keywords: DLBCL, BTK inhibitor, rituximab, lenalidomide, hematology